New results obtained by the French health authorities have further confirmed the “highly teratogenic nature” of valproate when used for the treatment of epilepsy and bipolar disorder in women during pregnancy, with as many as 4,100 French children potentially having suffered major birth defects since the drug’s launch in 1967.
The risk level varies depending on the disorder the drug is used for: the risk of major congenital malformations (MCMs)...




